Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. 1986

A Ohlsson, and J E Lindgren, and S Andersson, and S Agurell, and H Gillespie, and L E Hollister

The disposition of deuterium-labelled cannabidiol, 2H2-CBD, was studied in five young men who were marihuana smokers. The pattern of use ranged from infrequent to frequent use of the drug. Plasma concentrations, determined by mass fragmentography, were followed for 72 h after both intravenous administration of 20 mg 2H2-CBD and smoking of an estimated amount of 18.8-19.4 mg 2H2-CBD. Systemic availability after smoking was determined by comparing the areas under the plasma concentration versus time curves for the two treatments and was found to be 31 +/- 13%. A four-fold difference in the availability of the compound was noted for the five subjects. Based on the area under the curve and the dose after intravenous administration, a plasma clearance of 960-1560 ml min-1 was calculated. A terminal elimination phase was not reached at 72 h, but the kinetic parameters were estimated from the 72 h beta-elimination. A half-life of 31 +/- 4 h after smoking and 24 +/- 6 h after injection was estimated as well as a distribution volume of 2520 +/- 470 l (32.7 +/- 8.61 kg-1).

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D002185 Cannabidiol Compound isolated from Cannabis sativa extract. 1,3-Benzenediol, 2-(3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-, (1R-trans)-,Epidiolex
D002186 Cannabinoids Compounds having the cannabinoid structure. They were originally extracted from Cannabis sativa L. The most pharmacologically active constituents are TETRAHYDROCANNABINOL; CANNABINOL; and CANNABIDIOL. Cannabinoid
D002189 Marijuana Abuse Use of marijuana associated with abnormal psychological, social, and or occupational functioning. Cannabis Abuse,Cannabis Dependence,Cannabis-Related Disorder,Hashish Abuse,Marijuana Dependence,Marihuana Abuse,Abuse, Cannabis,Abuse, Hashish,Abuse, Marihuana,Abuse, Marijuana,Cannabis Related Disorder,Dependence, Cannabis,Dependence, Marijuana,Disorder, Cannabis-Related
D003903 Deuterium The stable isotope of hydrogen. It has one neutron and one proton in the nucleus. Deuterons,Hydrogen-2,Hydrogen 2
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Ohlsson, and J E Lindgren, and S Andersson, and S Agurell, and H Gillespie, and L E Hollister
March 1984, Archives of toxicology,
A Ohlsson, and J E Lindgren, and S Andersson, and S Agurell, and H Gillespie, and L E Hollister
January 1991, European journal of drug metabolism and pharmacokinetics,
A Ohlsson, and J E Lindgren, and S Andersson, and S Agurell, and H Gillespie, and L E Hollister
January 1987, European journal of clinical pharmacology,
A Ohlsson, and J E Lindgren, and S Andersson, and S Agurell, and H Gillespie, and L E Hollister
August 1983, Clinical pharmacology and therapeutics,
A Ohlsson, and J E Lindgren, and S Andersson, and S Agurell, and H Gillespie, and L E Hollister
January 1989, Contributions to nephrology,
A Ohlsson, and J E Lindgren, and S Andersson, and S Agurell, and H Gillespie, and L E Hollister
October 1979, Clinical pharmacology and therapeutics,
A Ohlsson, and J E Lindgren, and S Andersson, and S Agurell, and H Gillespie, and L E Hollister
December 1978, Research communications in chemical pathology and pharmacology,
A Ohlsson, and J E Lindgren, and S Andersson, and S Agurell, and H Gillespie, and L E Hollister
May 1984, Toxicology letters,
A Ohlsson, and J E Lindgren, and S Andersson, and S Agurell, and H Gillespie, and L E Hollister
April 1974, Journal of pharmacokinetics and biopharmaceutics,
A Ohlsson, and J E Lindgren, and S Andersson, and S Agurell, and H Gillespie, and L E Hollister
November 1994, The Journal of pharmacy and pharmacology,
Copied contents to your clipboard!